about
Transforming pain into beauty: on art, healing, and care for the spiritThe role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.The cultural expression of spiritual distress in IsraelCerebral Liposarcoma Embolus From Heart Metastasis Successfully Treated by Endovascular Extraction Followed by Cardiac SurgeryCorrection to: Human Development Index and its association with staff spiritual care provision: a Middle Eastern oncology studyIncrease in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction?The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot StudyCannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced MalignanciesTraining for awareness of one's own spirituality: A key factor in overcoming barriers to the provision of spiritual care to advanced cancer patients by doctors and nursesThe perception of Israeli oncology staff members regarding advance care planningHuman Development Index and its association with staff spiritual care provision: a Middle Eastern oncology studyA pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcomaCannabis treatment in hospitalized patients using the SYQE inhaler: Results of a pilot open-label study10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis
P50
Q26825710-2CDFE65B-C7FD-488E-9578-7ED8462E1224Q48127914-6F5E28C6-CE76-4A8B-9B35-CA97ADF4376FQ57071516-BD6BA42D-0AF5-4587-8161-BC6952E1CEBEQ89237348-C7C09D57-4AE9-4999-A8E0-DB6E71210204Q90258988-9EBD3EA5-6779-4D6C-B259-9C08CDBF3409Q90469796-86F341A9-0F23-4268-B1AC-F0D016EAC605Q90603553-0F3F8C99-0DB3-4217-A94A-66DEB9762B83Q91167804-07C76953-8FC7-453B-B66F-296D896EA5B0Q91312475-3B0C57DD-6C8E-46A6-A320-0E8F726B33AAQ92408543-5D753C24-F6B0-479A-B977-6392DBC82506Q92516147-BD40E2D0-9E3C-4CBA-8AC7-A7788F8708C4Q92606928-6C3BE8FC-D025-4DA6-A3A3-2C975A17F200Q92728039-F6948861-7C09-4FAE-8CBC-662BC3D83511Q93082226-5F7C52A1-2231-4B5A-9E74-45CCF0FB0AF0
P50
description
researcher
@en
name
Gil Bar-Sela
@en
type
label
Gil Bar-Sela
@en
prefLabel
Gil Bar-Sela
@en
P31
P496
0000-0001-6579-1841